1. Short title This Act may be cited as the Prescription Drug Supply Chain Pricing Transparency Act . 2. GAO study and report on price-related compensation and payment structures in the prescription drug supply chain Section 1860D–42 of the Social Security Act ( 42 U.S.C. 1395w–152 ) is amended by adding at the end the following new subsection: (e) GAO study and report on price-Related compensation and payment structures in the prescription drug supply chain (1) Study The Comptroller General of the United States (in this subsection referred to as the Comptroller General ) shall conduct a study on the use of compensation and payment structures related to a prescription drug’s price within the retail prescription drug supply chain. Such study shall include an overview of the following: (A) The type, magnitude, other features (such as the pricing benchmarks used), and prevalence of compensation and payment structures related to a prescription drug’s price, such as calculating fee amounts as a percentage of a prescription drug’s price, between intermediaries in the prescription drug supply chain, including— (i) pharmacy benefit managers; (ii) part D plan sponsors; (iii) drug wholesalers; (iv) pharmacies; (v) manufacturers; (vi) pharmacy services administrative organizations; (vii) brokers, auditors, consultants, and other entities that advise part D plan sponsors about pharmacy benefits or review part D plan sponsor contracts with pharmacy benefit managers